Introduction
Our recent studies have focused on the use of fresh tumour material to address the problem of anticancer drug resistance. The majority of laboratory investiga tions designed to study chemotherapeutic drug resis tance have used either in vitro tumour cell line models with acquired (in vitro derived) drug resistance, or in vivo animal models.
There are a number of difficulties which one may encounter when working with fresh tumour material. cannot be assumed to be a straightforward process, based on the assumption that those cells are not being regulated normally under in vivo conditions. Indeed, the growth and maintenance of malignant cells should be regarded as very complex processes which may be under the control of local and systemic stimuli, balanced against inhibitory regulators. It is commonly accepted that most tumour cells require numerous growth factors and nutrients but also that a low seeding density may prove lethal. It is interesting to note that metastatic tumours, especially those arising in pleural effusions or ascites, are generally more adaptable to in vitro condi tions and can be easily propagated. This may be because these tumour cells have already undergone several in vivo selections and are capable of producing their own supply of growth factors to enable them to become in dependent from their site of origin.
The most common criticism levelled at the use of fresh tumour samples relates to their heterogeneous nature, i.e. the presence of mesenchymal cells, blood cells and normal tissue. It is very important, therefore, to use a highly skilled staff to select samples of tumour material for in vitro studies, and this is generallybest left to the surgeon or histopathologist. Tumour cell content can be monitored by making cytospin prepara tions which can then be assessed by a trained cytologist.
Having described the numerous difficulties encoun tered by the use of fresh tumour material, we can men tion some very important advantages, such as their potential for direct testing of antitumour agents and the replacement of in vivo models. Clinical specimens are undoubtedly closer to in situ conditions than are con tinuous cell line models, and comparisons among indi vidual patients are possible. Our approach, therefore, aims to achieve a good laboratory-clinical interface so as to enable translation of laboratory data to the clinical problem of anticancer drug resistance.
Ovarian cancer is commonly treated by radical sur gery followed by chemotherapy. The overall survival rate, however, is low with <30% of women surviving 5 years. Drug resistance, therefore, remains a major obstacle for this disease group. Many mechanisms have been identified which confer resistance to ovarian tumour cells, but studies have focused primarily on cultured cell line models. Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumours. Although cure by surgery, with or without radiation therapy, is possible in a small proportion of cases, many patients with high grade, aggressive tumours will develop recur rent disease. STS are regarded as a chemorefractory disease group, having poor response rates to the first line agents doxorubicin and ifosfamide.
Multidrug resistance (MDR) is characterised by broad cross-resistance of tumour cells to a diverse range of (generally) natural product cytotoxic agents. This is thought to be related to the presence of a 170kDa membrane glycoprotein called P-glycoprotein (Pgp).l,2 Pgp is thought to act as an energy-dependent drug efflux pump, the presence of which can be shown to result in lowered intracellular drug content. Multidrug resistance-protein (MRP), multidrug resistance-protein,3 a 190kDa protein has also been shown to give rise to an MDR phenotype and may even be coexpressed with Pgp. 4 The cytosolic protein LRP, lung-resistance-asso ciated protein,5 may also be implicated in an MDR phenotype, although less is known about this more recently discovered drug resistance marker.
Strategies have been proposed with the purpose of reversing MDR by pharmacological intervention. This has focused most notably on the use of membraneactive agents, such as calcium-channel blockers6 and cyclosporins.' These so-called MDR modulating agents are structurally diverse and, although their precise mode of MDR reversal has yet to be clarified, they are able to block drug transport processes mediated by Pgp and to a lesser extent MRP, thus enhancing chemo sensitivity. In the present studies we have focused on the use of the non-immunosuppressive cyclosporin PSC-833, which has undergone clinical evaluation in a number of tumour types. We have attempted to look at the utility of such an approach in ovarian cancer and STS.
In common with many other tumour types, muta tions in the p53 gene have been identified in human sarcomas, and additionally amplification of a p53-regulating gene MDM2. 8 Both observations have been linked with a poor prognosis. These processes may contribute toward tumorigenesis and/or the develop ment of chemoresistant disease in STS, which the pres ent studies have attempted to address.
M aterials and Methods

Sample preparation
Samples of fresh ovarian cancer were subjected to centrifugation (in the case of ascitic fluid), or to mechanical disaggregation with crossed scalpels, fol lowed by density gradient centrifugation if required, to remove erythrocytes and necrotic cells. Cells were suspended and cultured in RPMI-1640 medium (GIBCO BRL, Gaithersberg, MD, USA) supplemented with 10% foetal calf serum. Primary sarcoma cultures were established by mechanical disaggregation, as above, followed by digestion with collagenase treat ment (500-1,000 IU/ml). Cell suspensions were then cultured in Ham's F12 medium supplemented with 20% serum. Cytospin preparations were made of all samples for morphological assessment of tumour cell content and for subsequent immunocytochemical analyses. achieved.
Use of MDR modulators: Table 2 shows examples of ovarian cancer samples which were shown to be che mosensitised by cyclosporins, in the presence of doxor ubicin, using the MTT assay. Data for taxol are not shown, but sensitisation ratios were, in general, found to be lower than than those for doxorubicin. Twentyseven samples were tested for Pgp function by flow cytometry, of which 17 (63%) were shown to be pos itive. The median ratio obtained for positive samples was 1.07. For the majority of samples giving a positive functional assay sensitisation ratios of >1.0 were seen.
Relationship between survival and Pgp expression: We found a weak correlation between Pgp expression 
